LENZ — LENZ Therapeutics, Inc.

LENZ Therapeutics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: LENZ ended Q4 2025 with approximately $292.3 million in cash, cash equivalents, and marketable securities, remaining debt-free.
• Revenue: The company reported net product revenues of approximately $1.6 million from the launch of VIZZ, with over 20,000 monthly paid prescriptions.
• Operating Expenses: Total Q4 operating expenses were about $40 million, with $39.6 million attributed to SG&A, primarily driven by sales and marketing efforts for VIZZ.
• Net Loss: The net loss for Q4 was $35.9 million, resulting in a loss per share of $1.16, compared to a loss of $12.7 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Product Launch: VIZZ, a presbyopia treatment, has been well-received, with over 45,000 boxes sold and 10,000 prescribing eye care professionals (ECPs) engaged.
• Market Positioning: The company is focused on establishing VIZZ as a new treatment category, emphasizing its unique efficacy and broad applicability.
• Sales Force Expansion: LENZ is increasing its sales force from 88 to 117 representatives to enhance physician engagement and prescription frequency.
• Direct-to-Consumer (DTC) Campaign: The DTC campaign featuring Sarah Jessica Parker has generated significant consumer engagement, with website traffic increasing by up to 10x during national activations.

3. Forward Guidance and Outlook

• Patient Adoption: The company expects an acceleration in new patient starts as both physician and consumer awareness grow, projecting a more meaningful impact on prescription volume in the second half of 2026.
• Refill Expectations: Early signals suggest encouraging refill behavior, with patients moving from 1-month to 3-month prescriptions, although specific refill metrics will be monitored over the coming quarters.
• Global Expansion: LENZ anticipates potential approvals for VIZZ in multiple international markets by early 2027, with ongoing regulatory submissions in several countries.

4. Challenges and Points of Concern

• Gradual Adoption: The pace of new patient adoption is slower than initially anticipated, typical for new treatment categories, which may affect short-term revenue growth.
• Market Education: There is a need to correct misconceptions among ECPs regarding the appropriate patient demographics for VIZZ, as some still associate it primarily with early presbyopes.
• Competitive Landscape: The company faces competition from established products like VUITY, which may impact market penetration and prescriber habits.

5. Notable Q&A Insights

• Sampling Strategy: Over 90% of new patients started with a sample, indicating the effectiveness of the sampling strategy in driving adoption.
• Prescriber Behavior: The top 1,000 prescribers are filling 40% more scripts than comparable prescribers of VUITY, demonstrating strong initial engagement with VIZZ.
• Consumer Demographics: The target demographic for VIZZ includes a significant portion of patients with prior LASIK and contact lens users, aligning with the company’s marketing strategy.
• DTC Metrics: The DTC campaign is showing positive early indicators, with click-through rates and impressions exceeding benchmarks, although it typically takes 2 quarters to see a direct correlation to prescription trends.

Overall, LENZ Therapeutics is positioned for growth with a strong financial foundation and a promising product launch, but it must navigate challenges related to market education and adoption dynamics.